Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The antibody-drug conjugate Tivdak led to remission in 24% of cervical cancer patients.
Keytruda plus chemotherapy reduced the risk of death by 27% in people with locally advanced or metastatic disease.
The Food and Drug Administration recently approved the checkpoint inhibitor Keytruda (pembrolizumab).
Keytruda after kidney cancer surgery prolonged disease-free survival rates in patients at high risk for recurrence.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.
This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.
A combination of two immunotherapy drugs may be more effective than the current standard treatment, chemotherapy.
In patients at high risk of relapse, adjuvant therapy with Keytruda prolonged disease-free survival.
75% of people treated with a combination of immunotherapy, targeted therapy and chemotherapy saw their tumors shrink.
However, a majority of these chronic immune-related side effects were mild.
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.